Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial
Antoni Chan, Jon Wood, Lachrissa Burns, Thomas Kumke, Bengt Hoepken, Mindy Kim, Lars Bauer, Kirsten Mackay, Karl Gaffney · 2026
Read Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial by Antoni Chan, Jon Wood, Lachrissa Burns, Thomas Kumke, Bengt Hoepken, Mindy Kim, Lars Bauer, Kirsten Mackay, Karl Gaffney (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13425177.txt.
Description
Antoni Chan and co-authors report patient-reported outcomes from a trial of dose reduction in early axial spondyloarthritis. Their 2026 paper covers the randomized phase of the C-OPTIMISE study. Patients with this spinal inflammatory disease had reached sustained remission on certolizumab pegol, a biologic drug, after forty-eight weeks of open treatment.
Of seven hundred thirty-six patients, about forty-four percent held remission at that point. They were then assigned in equal shares to full dose, reduced dose, or placebo for another forty-eight weeks. Scores for disease activity, function, night pain, and quality of life were tracked. Gains held up on both drug doses through week ninety-six, the authors report.
Catalog record
| CREATOR | Antoni Chan, Jon Wood, Lachrissa Burns, Thomas Kumke, Bengt Hoepken, Mindy Kim, Lars Bauer, Kirsten Mackay, Karl Gaffney |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |